Country share of clinical trial country-uses

STO-REC-STATMKSSJ1T3 Research
16%

United States · 2021–2023

Country share of clinical trial country-uses in United States stood at 16% in 2021–2023 (IQVIA).

Original source
Publisher
IQVIA
Authority tier
T3 Research
Locator
Country utilization is heavily consolidated in U.S., China and Western European countries
Retrieved
15 Sep 2026
Status
Verified

What the source says

The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.

Verbatim extraction verified: The figure 16% is directly attested in the quoted passage (Country utilization is heavily consolidated in U.S., China and Western European countries).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1
MLA
IQVIA Institute. "Rethinking Clinical Trial Country Prioritization." 2023, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1.
Chicago
IQVIA Institute. "Rethinking Clinical Trial Country Prioritization." 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1.
BibTeX
@misc{iqvia2023country5774x1, author = {{IQVIA Institute}}, title = {Rethinking Clinical Trial Country Prioritization}, year = {2023}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATMKSSJ1 T3 Research

Primary Source

Publisher
IQVIA Institute · homepage ↗
Authority tier
Tier 3 · Industry & Research
Report
Rethinking Clinical Trial Country Prioritization
Type
Press release
Published
Locator
Country utilization is heavily consolidated in U.S., China and Western European countries
Retrieved
15 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_MKSSJ11HJT01770TDNK75774X1